Comparative Pharmacology
Head-to-head clinical analysis: DOXY 200 versus MECLAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOXY 200 versus MECLAN.
DOXY 200 vs MECLAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the mRNA-ribosome complex, and thus inhibiting peptide chain elongation. It is bacteriostatic and active against a broad range of gram-positive and gram-negative bacteria, as well as atypical organisms.
Meclizine is an antihistamine with central anticholinergic properties. It blocks histamine H1 receptors and exerts antiemetic effects via inhibition of the vestibular system and chemoreceptor trigger zone.
200 mg orally once daily or 100 mg orally every 12 hours.
250 mg orally three times daily for 7-14 days; for sinusitis: 500 mg three times daily.
None Documented
None Documented
Terminal elimination half-life: 18–22 hours in adults with normal renal function; prolonged in renal impairment (up to 40 hours).
Terminal elimination half-life: 12-15 hours in adults; prolonged in renal impairment (up to 30 hours).
Renal: 40% unchanged via glomerular filtration; Biliary/fecal: 20–25% as active drug and metabolites; remainder as inactive metabolites.
Renal excretion of unchanged drug and metabolites: ~70%; fecal/biliary: ~30%.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic